» BiPar Sciences Expands Phase 2 <b>Clinical Trials</b> Of BSI-201, A Novel <b>...</b>
BiPar Sciences, Inc. announced the expansion of Phase 2 clinical trial programs for its lead product, BSI-201, in ovarian cancer. This is the third major clinical trial of BSI-201 that BiPar has…